Manufacturer record
GBN Pharmaceuticals: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
2 batches manufactured by GBN Pharmaceuticals were declared Not of Standard Quality in February 2026. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: PH5V152, Pheniramine Maleate Injection IP (exp May 2027). DTL Jaipur (state lab) found it not of standard quality: The sample does not conform to the IP with respect to Sterility. Listed in the February 2026 alert.
Records by type
2 records linked to GBN Pharmaceuticals in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Pheniramine Maleate Injection IP | Batch PH5V152Mfg Jun 2025 · Exp May 2027 | The sample does not conform to the IP with respect to Sterility.Sterility | DTL JaipurState lab | Feb 2026 |
| Pheniramine Maleate Injection IP | Batch PH5V111BMfg May 2025 · Exp Apr 2027 | The sample does not conform to the IP with respect to Sterility.Sterility | DTL JaipurState lab | Feb 2026 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.